The estimated Net Worth of Olsen Per Wold is at least $14.3 Milhão dollars as of 10 January 2023. Mr. Wold owns over 22,027 units of Gilead Sciences stock worth over $13,842,925 and over the last 15 years he sold GILD stock worth over $0. In addition, he makes $449,977 as Independent Director at Gilead Sciences.
Per has made over 9 trades of the Gilead Sciences stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 22,027 units of GILD stock worth $1,782,865 on 10 January 2023.
The largest trade he's ever made was buying 55,000 units of Gilead Sciences stock on 13 June 2022 worth over $92,950. On average, Per trades about 5,271 units every 133 days since 2010. As of 10 January 2023 he still owns at least 171,027 units of Gilead Sciences stock.
You can see the complete history of Mr. Wold stock trades at the bottom of the page.
Per Wold-Olsen serves as Independent Director of the Company. Mr. Wold-Olsen has served as the Chair of Gilead’s Health Policy Advisory Board since 2007. From 2005 to 2006, he served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S and Oncopeptides AB. In addition, he is the Chairman of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria.
As the Independent Director of Gilead Sciences, the total compensation of Per Olsen at Gilead Sciences is $449,977. There are 10 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.
Per Olsen is 72, he's been the Independent Director of Gilead Sciences since 2010. There are 1 older and 24 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
Olsen's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger, eJohn F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: